These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 7858530

  • 41. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP, Baskar D, Urban FF, Friedman MS, Braun TM, McDonagh KT.
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [Abstract] [Full Text] [Related]

  • 42. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N, Levy R.
    J Immunol; 1987 Aug 01; 139(3):971-6. PubMed ID: 3496394
    [Abstract] [Full Text] [Related]

  • 43. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
    Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith JW, Alvord WG, Creekmore SP, Fenton RG, Gause BL, Holmlund J.
    J Clin Oncol; 1993 Apr 01; 11(4):652-60. PubMed ID: 8257476
    [Abstract] [Full Text] [Related]

  • 44. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct 01; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 45. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.
    Kwak LW, Campbell MJ, Levy R.
    Cancer Res; 1992 Aug 01; 52(15):4117-20. PubMed ID: 1638524
    [Abstract] [Full Text] [Related]

  • 46. Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
    Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW, Sharfman WH, Longo DL.
    J Immunother Emphasis Tumor Immunol; 1996 Jul 01; 19(4):296-308. PubMed ID: 8877723
    [Abstract] [Full Text] [Related]

  • 47. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML, Longo DL, Wetzel HE, Tribble H, Alvord WG, Kwak LW, Leonard AS, Ullmann CD, Curti BD, Ochoa AC.
    Blood; 1997 Apr 01; 89(7):2529-36. PubMed ID: 9116299
    [Abstract] [Full Text] [Related]

  • 48. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
    Gold JE, Osband ME.
    Clin Immunol Immunopathol; 1994 Jun 01; 71(3):325-32. PubMed ID: 7911078
    [Abstract] [Full Text] [Related]

  • 49. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
    Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Gause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL.
    J Clin Oncol; 1998 Aug 01; 16(8):2752-60. PubMed ID: 9704728
    [Abstract] [Full Text] [Related]

  • 50. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
    Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E.
    Cancer Invest; 1992 Aug 01; 10(3):221-7. PubMed ID: 1581831
    [Abstract] [Full Text] [Related]

  • 51. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
    Gold JE, Osband ME.
    Eur J Cancer; 1994 Aug 01; 30A(12):1871-82. PubMed ID: 7880620
    [Abstract] [Full Text] [Related]

  • 52. Interleukin-2 and interleukin-7 augment the cytolytic activity and expand the antitumor killing spectrum of alpha CD3-induced activated killer cells: potential use in the immunotherapy of non-immunogenic tumors.
    Ting CC, Wang J, Yang Y.
    Cancer Immunol Immunother; 1996 Dec 01; 43(5):283-92. PubMed ID: 9024505
    [Abstract] [Full Text] [Related]

  • 53. Therapy of leukemia by nonimmune syngeneic spleen cells.
    Cheever MA, Greenberg PD, Fefer A.
    J Immunol; 1980 May 01; 124(5):2137-42. PubMed ID: 7365249
    [Abstract] [Full Text] [Related]

  • 54. [Elimination of syngeneic lymphoma cells from a mouse bone marrow suspension using immune cytotoxic lymphocytes sensitized in vitro].
    Mitskevich PB, Murzenok PP, Voĭtenok NN.
    Eksp Onkol; 1985 May 01; 7(4):67-8. PubMed ID: 3876204
    [Abstract] [Full Text] [Related]

  • 55. Adoptive transfer of anti-cytomegalovirus effect of interleukin-2-activated bone marrow: potential application in transplantation.
    Agah R, Charak BS, Chen V, Mazumder A.
    Blood; 1991 Aug 01; 78(3):720-7. PubMed ID: 1650263
    [Abstract] [Full Text] [Related]

  • 56. Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy.
    Cao X, Li Q, Ju DW, Wang Q, Tao Q, Wang J.
    Transplantation; 1999 May 15; 67(9):1242-50. PubMed ID: 10342316
    [Abstract] [Full Text] [Related]

  • 57. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
    Gold JE, Masters TR, Osband ME.
    J Surg Res; 1995 Aug 15; 59(2):279-86. PubMed ID: 7543632
    [Abstract] [Full Text] [Related]

  • 58. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.
    Fehniger TA, Carson WE, Mrózek E, Caligiuri MA.
    Blood; 1997 Nov 01; 90(9):3647-53. PubMed ID: 9345049
    [Abstract] [Full Text] [Related]

  • 59. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2.
    Cheever MA, Greenberg PD, Fefer A.
    J Immunol; 1981 Apr 01; 126(4):1318-22. PubMed ID: 6970768
    [No Abstract] [Full Text] [Related]

  • 60. [The characteristics of the activated killer cells (AK) induced in vitro with recombinant IL-2 (rIL-2)].
    Iwahashi T, Kuribayashi K, Takao T, Takano Y, Saito K.
    Arerugi; 1986 Oct 01; 35(10):1047-55. PubMed ID: 3492990
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.